Open Label, Phase II Study of Anti - Programmed Death - Ligand 1 Antibody, Durvalumab (MEDI4736), in Combination With Chemotherapy for the First-Line Treatment of Unresectable Mesothelioma

Trial Profile

Open Label, Phase II Study of Anti - Programmed Death - Ligand 1 Antibody, Durvalumab (MEDI4736), in Combination With Chemotherapy for the First-Line Treatment of Unresectable Mesothelioma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Dec 2017

At a glance

  • Drugs Cisplatin (Primary) ; Durvalumab (Primary) ; Pemetrexed (Primary)
  • Indications Mesothelioma; Pleural disorders
  • Focus Therapeutic Use
  • Acronyms PrE0505
  • Most Recent Events

    • 01 May 2017 Status changed from not yet recruiting to recruiting.
    • 03 Mar 2017 Planned End Date changed from 1 Nov 2020 to 1 Dec 2020.
    • 03 Mar 2017 Planned primary completion date changed from 1 Jul 2020 to 1 Aug 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top